Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cellviva Inc. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This workload is assigned to 1 distinct examiner and 1 distinct art unit, reflecting a highly localized prosecution status. The company is currently navigating a single point of review for its pending intellectual property, which centralizes the administrative and legal efforts required for these filings. This structure allows the applicant to focus on the specific technical requirements of 1 distinct art unit.
The busiest examiner for this portfolio is LOCKARD, JON MCCLELLAND, who is managing 1 pending office action. This examiner is responsible for the only active office action currently pending for Cellviva Inc. With 1 distinct art unit involved, the technical review is confined to a specific area of biotechnology. This structure allows for a focused prosecution strategy that addresses the specific feedback and examination style of LOCKARD, JON MCCLELLAND. Practitioners should monitor the specific timelines of this examiner to ensure a timely response to the 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LOCKARD, JON MCCLELLAND | 1 | 74.4% | +27.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17997688 | COMPOSITIONS COMPRISING ANTI-VEGF AND NANOPARTICLES AND METHODS OF USING THE SAME FOR THE TREATMENT OF ABNORMAL OR EXCESSIVE ANGIOGENESIS | LOCKARD, JON MCCLELLAND | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17997688 | COMPOSITIONS COMPRISING ANTI-VEGF AND NANOPARTICLES AND METHODS OF USING THE SAME FOR THE TREATMENT OF ABNORMAL OR EXCESSIVE ANGIOGENESIS | LOCKARD, JON MCCLELLAND | — |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17997688 | COMPOSITIONS COMPRISING ANTI-VEGF AND NANOPARTICLES AND METHODS OF USING THE SAME FOR THE TREATMENT OF ABNORMAL OR EXCESSIVE ANGIOGENESIS | LOCKARD, JON MCCLELLAND | 1647 | §102§103§112 | Non-Final OA | — | Pending | Nov 01, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCellviva Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jon Mcclelland Lockard has the most, with 1 of Cellviva Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
